Budget Amount *help |
¥93,340,000 (Direct Cost: ¥71,800,000、Indirect Cost: ¥21,540,000)
Fiscal Year 2014: ¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2013: ¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2012: ¥20,020,000 (Direct Cost: ¥15,400,000、Indirect Cost: ¥4,620,000)
Fiscal Year 2011: ¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2010: ¥20,410,000 (Direct Cost: ¥15,700,000、Indirect Cost: ¥4,710,000)
|
Outline of Final Research Achievements |
We investigated the pathomechanism for adult-onset motor neuron diseases: amyotrophic lateral sclerosis (ALS) and spinal and bulbar muscular atrophy (SBMA), and identified HSF-1, TGF-beta, CGRP1, and PPARgamma, as common pathigenic molecules for these disorders. We also clarified that compounds that restore the function of these molecules ameliorate motor neuron degeneration in animal models of ALS and SBA.
|